tenofovir has been researched along with HIV in 175 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (2.86) | 18.2507 |
2000's | 36 (20.57) | 29.6817 |
2010's | 98 (56.00) | 24.3611 |
2020's | 36 (20.57) | 2.80 |
Authors | Studies |
---|---|
Babusis, D; Boojamra, CG; Chen, J; Cihlar, T; Douglas, J; Grant, D; Hui, HC; Kim, CU; Lin, KY; Mackman, RL; Markevitch, DY; Petrakovsky, O; Prasad, V; Ray, A; Vela, J; Zhang, L | 1 |
Balzarini, J; Flynn, ÁS; Hinsinger, K; McGuigan, C; Pertusati, F; Powell, N; Tristram, A | 1 |
Balzarini, J; Camarasa, MJ; Carrero, P; Doyagüez, EG; Leyssen, P; Madrona, A; Neyts, J; Paeshuyse, J; Peréz-Pérez, MJ; Quesada, E; Rivero-Buceta, E; San-Félix, A | 1 |
Balzarini, J; Camarasa, MJ; Colomer, I; Doyagüez, EG; Liekens, S; Mathys, L; Noppen, S; Pérez-Pérez, MJ; Quesada, E; Rivero-Buceta, E; San-Félix, A | 1 |
Camarasa, MJ; de Castro, S | 1 |
Bazzi, R; Roa, PE | 1 |
Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F | 1 |
Chang, SY; Chen, GJ; Hsieh, SM; Huang, SH; Huang, YC; Hung, CC; Liu, WC; Liu, WD; Sheng, WH; Su, LH; Su, YC; Sun, HY | 1 |
Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
De Clercq, E | 4 |
Allerton, J; Castillo-Mancilla, J; Hsiao, NY; Hu, NC; Kabanda, S; Lesosky, M; Malaba, TR; Myer, L; Odayar, J; Orrell, C; Phillips, TK; Wiesner, L | 1 |
Bamford, L; Burkholder, GA; Cachay, ER; Christopoulos, K; Crane, HM; Delaney, JAC; Eron, JJ; Gravett, RM; Jacobson, JM; Keruly, J; Kitahata, MM; Ma, J; Martin, J; Mayer, KH; Moore, RD; Nance, RM; Napravnik, S; Saag, MS; Whitney, BM | 1 |
Adeyeye, A; Agyei, Y; Anderson, PL; Bushman, LR; Chau, G; Cohen, MS; Cummings, V; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Fogel, JM; Ford, S; Haines, CD; Hanscom, B; Hendrix, CW; Hosseinipour, M; Hughes, JP; Hunidzarira, P; Kofron, R; Marzinke, MA; Mathew, CA; Mellors, J; Mpendo, J; Nair, G; Persaud, D; Petropoulos, C; Piwowar-Manning, E; Richardson, P; Rinehart, A; Rooney, JF; Spooner, E; St Clair, M; Sullivan, P | 1 |
Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K | 1 |
Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A | 1 |
Liu, W; Yan, B; Yu, S | 1 |
Barham, L; Dzinamarira, T; Mhango, M; Moyo, E; Musuka, G | 1 |
Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Calmy, A; Günthard, HF; Hofmann, E; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Suter-Riniker, F; Wandeler, G | 1 |
Cone, R; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, CW; Hoang, T; Marzinke, MA; Myers, R; Rohan, LC; Villinger, F; Wang, L; Xiao, P | 1 |
Fan, L; Gao, L; Hu, Y; Huang, R; Li, L; Ma, P; Qiu, C; Wu, Y; Yu, A; Zhang, D | 1 |
Anderson, PL; Glidden, DV; Marzinke, MA | 1 |
Del Amo, J | 1 |
Agil, D; Althoff, KN; Augenbraun, M; Bastarache, L; Benning, L; Coburn, SB; Gangireddy, S; Gebo, KA; Gordon, KS; Horberg, MA; Jefferson, C; Lang, R; Lea, AN; Leyden, WA; Marafino, BJ; Marconi, VC; Napravnik, S; Park, LS; Silverberg, MJ; Skarbinski, J; Sofrygin, O; Williams, C | 1 |
Bernasconi, E; Burkhalter, F; Calmy, A; Fellay, J; Günthard, HF; Hasse, B; Kahlert, CR; Kouyos, RD; Lamy, O; Ledergerber, B; Marzolini, C; Ryom, L; Schoepf, IC; Schwenke, JM; Tarr, PE; Thorball, CW; Wandeler, G | 1 |
Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
Kitazawa, T; Wakabayashi, Y; Yoshino, Y | 1 |
Ishikawa, K; Kawai, F; Mori, N | 1 |
Anderson, PL; Bekker, LG; Boily, MC; Celum, CL; Delany-Moretlwe, S; Dimitrov, D; Donnell, DJ; Mgodi, NM; Mitchell, KM; Moore, M; Stansfield, S | 1 |
Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
Gusmão, MBF; Melo, LC; Oliveira, VV; Santos, NMDS | 1 |
Alejandria, M; Arcangel, L; Arevalo, GM; Ching, PR; Destura, R; Dungca, NT; Leyritana, K; Lim, J; Mendoza, KAR; Palaypayon, NS; Peñalosa-Ramos, C; Salvana, EMT; Samonte, GMJ; Schwem, BE; Solante, R; Tactacan-Abrenica, RJ; Telan, E; Tonga, AD; Trinidad, LF | 1 |
Atukunda, M; Ayieko, J; Balzer, LB; Black, D; Brown, LB; Bukusi, EA; Camlin, CS; Chamie, G; Charlebois, ED; Clark, TD; Cohen, CR; Gandhi, M; Havlir, DV; Jain, V; Kabami, J; Kamya, MR; Koss, CA; Kwarisiima, D; Marquez, C; Mwangwa, F; Mwinike, Y; Olilo, W; Owaraganise, A; Peng, J; Petersen, ML; Rooney, JF; Ruel, TD; Sang, N; Zhang, K | 1 |
Bickel, M; Gillor, D; Grunwald, S; Härter, G; Hoffmann, C; Krznaric, I; Mueller, MC; Müller, M; Postel, N; Roider, J; Römer, K; Schabaz, F; Schewe, K; Spinner, CD | 1 |
Alonso-Castro, AJ; Alvarez-Alvarez, RM; Del Carmen Preciado-Puga, M; Del Rocio Ibarra-Reynoso, L; Lazo-de-la-Vega-Monroy, ML; Ruiz-Noa, Y; Ruiz-Padilla, AJ; Sánchez-Barajas, M | 1 |
Anderson, PL; Defechereux, P; Gandhi, M; Grant, RM; Jee, K; Johannessen, D; Kearney, MF; Kuncze, K; Lowery, B; McDonald, C; McFarlane, JR; Okochi, H; Phung, N; Shuford, JA; Smith, DK; Spindler, J; Spinelli, MA | 1 |
Baeten, JM; Berard, AR; Birse, K; Burgener, A; Calienes, FL; Cameron, MJ; Cartwright, M; Collier, AC; Cranston, RD; Curlin, ME; Golden, JB; Hladik, F; Holtz, TH; Hughes, SM; Irungu, E; Katabira, E; Lama, JR; Levy, CN; Lingappa, JR; Mackelprang, R; McElrath, MJ; McGowan, I; Mugo, N; Muwonge, T; Noël-Romas, L; Pandey, U; Richardson, B; Stekler, JD; Stevens, CE; Vojtech, L | 1 |
Patel, RR; Rowan, SE; Schneider, JA; Smith, DK | 1 |
Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
Baeten, JM; Donnell, D; Gandhi, M; Glidden, DV; Hendrix, C; Marzinke, M; Mugo, N; Mujugira, A; Rodrigues, WC; Spinelli, MA; Stalter, RM; Vincent, M; Wang, G | 1 |
Chang, SF; Chang, SY; Hsiao, YY; Huang, YC; Hung, CC; Kuo, CH; Lee, YL; Lin, YT; Luo, YZ | 1 |
Kaltashov, IA; Xu, S | 1 |
Adams-Huet, B; Bedimo, RJ; Brown, G; Castanon, R; Farukhi, I; Maalouf, NM; Moore, T; Poindexter, J; Tebas, P; Turner, D | 1 |
Heldwein, S; Jaeger, H; Noe, S; Oldenbuettel, C; Pascucci, R; Ruecker, K; von Krosigk, A; Wiese, C; Wolf, E | 1 |
Anderson, SM; Chandra, N; Cottrell, M; Doncel, GF; Kashuba, A; Kimble, T; Schwartz, JL; Sykes, C; Thurman, AR; Yousefieh, N | 1 |
Farcasanu, M; Kwon, DS | 1 |
Hope, TJ | 1 |
Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Post, F; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
Hsieh, E; Yin, MT | 1 |
Bennett, M; Coca, SG; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Liu, A; Mehrotra, M; Parikh, CR; Scherzer, R; Shlipak, MG | 1 |
Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N | 1 |
Folayan, MO; Peterson, K | 1 |
Gordon, CM; Havens, PL; Kapogiannis, BG; Long, D; Mulligan, K; Price, G; Schuster, GU; Stephensen, CB; Wilson, CM | 1 |
Chen, QY; Fang, ZL; Harrison, TJ; Hu, LP; Jia, HH; Li, KW; Liang, SJ; Ren, CC; Wang, C; Wang, XY; Yang, QL | 1 |
Tartaglia, A | 1 |
Naing, C; Poovorawan, Y; Tong, KS | 1 |
Dai, JH; Hu, Y; Huang, AL; Liang, H; Peng, B; Zhang, JY; Zhang, Y; Zhong, XN | 1 |
Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
Kan, W; Leng, X; Liao, L; Liu, P; Ruan, Y; Shao, Y; Wang, J; Xing, H; Xu, W; Yan, J; You, Y; Zuo, Z | 1 |
Hamers, RL; Inzaule, SC; Rinke de Wit, TF | 1 |
Bumpus, NN; Hamlin, AN; Tillotson, J | 1 |
Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Gardner, EM; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH | 1 |
Atkinson, A; Bernasconi, E; Bonnet, F; Dabis, F; Dufour, JF; Fehr, J; Gjærde, LK; Kraus, D; Mauron, E; Neau, D; Peters, L; Rauch, A; Reiss, P; Rockstroh, J; Smit, C; van der Valk, M; Wandeler, G | 1 |
Bastard, JP; Capeau, J; Costagliola, D; Eme, AL; Esteve, E; Fellahi, S; Guiard-Schmid, JB; Lebrette, MG; Lescure, FX; Pialoux, G; Plaisier, E; Ronco, P | 1 |
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Mangin, E; Marshall, W; Martinho, M; Panebianco, D; Talaty, JE; Valesky, R; Yeh, WW; Zhu, Y | 1 |
Bumpus, NN; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Mallayasamy, S; Marzinke, MA; Sale, M | 1 |
Wyles, DL | 1 |
Baeten, JM; Bangsberg, DR; Haberer, JE; Hendrix, C; Jaggernath, M; Kriel, Y; Matthews, LT; O'Neil, K; Psaros, C; Smit, JA; Smith, PM; Ware, NC; Wirth, K | 1 |
Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
Bachman, S; Cong, ME; García-Lerma, JG; Hanson, DL; Heneine, W; Mitchell, J; Sweeney, E | 1 |
Charalambous, S; Churchyard, GJ; Grant, AD; Hoffmann, CJ; Lewis, JJ; Velen, K | 1 |
Bekker, LG; Kaplan, R; Lawn, SD; Njuguna, C; Orrell, C; Wood, R | 1 |
Casado, JL; Del Palacio, M; Moreno, A; Moreno, S; Safont, P; Wikman, P | 1 |
Boyd, A; Brichler, S; Chevallier-Queyron, P; Delaugerre, C; Girard, PM; Gordien, E; Lacombe, K; Maylin, S; Miailhes, P; Scholtès, C | 1 |
Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS | 1 |
Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L | 1 |
Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC | 1 |
Ayala-Sims, VA; Fulco, PP | 1 |
Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
Debyser, Z; Schrijvers, R | 1 |
Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
Chi, BH; Emge, D; Mulenga, L; Mweemba, A; Vinikoor, MJ; Wandeler, G; Zanolini, A | 1 |
Dinh, C; Herold, BC; Kiser, P; Lo, Y; McNicholl, JM; Pau, CP; Smith, JM; Srinivasan, P; Teller, R; Zhang, J | 1 |
Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
Abdool Karim, SS; Eshleman, SH; Garrett, N; Karim, QA; Laeyendecker, O; Longosz, AF; Naranbhai, V; Nason, M; Quinn, TC; Redd, AD | 1 |
Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
Cong, ME; Dobard, CW; Garcia-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Makarova, N; Novembre, FJ; Pau, CP; Sharma, S; West, R | 1 |
Brooks, JT; Bush, T; Conley, L; Escota, GV; Hammer, J; Henry, K; Kojic, EM; Lichtenstein, KA; Mondy, K; Önen, N; Overton, ET; Patel, P; Wood, KC | 1 |
Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA | 1 |
Baeten, JM; Celum, C; Donnell, D; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; McCoy, CO; Mugo, N; Thomas, KK; Warth, C; Weis, JF | 1 |
Béguelin, C; Moradpour, D; Rauch, A; Sahli, R; Suter, F; Vazquez, M; Wandeler, G | 1 |
Casadellà, M; Gordon, M; Kuritzkes, DR; Marconi, VC; Noguera-Julian, M; Paredes, R; Parera, M; Rodriguez, C; Sunpath, H | 1 |
Ebell, MH | 1 |
Bogner, JR; Hilge, R; Schrader, S; Seybold, U; Zeder, AJ | 1 |
Babin, FX; Balathandan, TP; Chinnakali, P; Clevenbergh, PA; Das, M; Harries, AD; Lwin, TT; Shwe, M; Thein Than Tun, S; Thiha, N; Tin, HH; Yi, Y | 1 |
Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH | 1 |
Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 1 |
Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH | 1 |
Deray, G; Isnard-Bagnis, C; Rouvier, P; Simon-Tillaux, N; Tourret, J | 1 |
Decloedt, EH; Joska, JA; Lesosky, M; Maartens, G | 1 |
Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B | 1 |
Fiorante, S; Pulido, F | 1 |
Arribas López, JR; Bernardino de la Serna, JI; Mora Rillo, M | 1 |
López Bernaldo de Quirós, JC | 1 |
Mallolas, J | 1 |
Cheshenko, N; Fakioglu, E; Guzman, E; Herold, BC; Keller, MJ; Mesquita, PM; Mhatre, M; Wilson, SS | 1 |
Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
Mohammadi, D | 1 |
Boucher, CA; van de Vijver, DA | 1 |
Murphy, B; Romanelli, F | 1 |
Cerini, C; Fabiano, V; Giacomet, V; Mora, S; Pivetti, V; Puzzovio, M; Viganò, A; Zamproni, I; Zuccotti, GV | 1 |
Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH | 1 |
Hachiya, A; Kirby, KA; Kodama, EN; Michailidis, E; Oka, S; Sakagami, Y; Sarafianos, SG; Schuckmann, MM; Singh, K | 1 |
Aung, W; Cong, ME; Dobard, C; Garcia-Lerma, JG; Heneine, W; Mitchell, J; Sharma, S; Youngpairoj, AS | 1 |
Cong, ME; Curtis, KA; García-Lerma, JG; Hanson, D; Heneine, W; Kennedy, MS; Luckay, A; Owen, SM; Smith, J; Youngpairoj, AS; Zheng, Q | 1 |
Cotter, AG; Powderly, WG | 1 |
Cocohoba, J; Gruta, C; John, MD; Lao, CK | 1 |
Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
Cellini, M; Gabiano, C; Giacomet, V; Manfredini, V; Mora, S; Puzzovio, M; Salvini, F; Stucchi, S; Tamburrini, E; Viganò, A; Zuccotti, GV | 1 |
Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
Adams, JL; Kashuba, AD | 1 |
Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
Abdool Karim, SS; Baxter, C | 1 |
Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM | 1 |
Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ | 1 |
Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
Aries, SP; Dalhoff, K; Kramme, E; Schaaf, B; Steinhoff, J | 1 |
Asensi, V; Barrios, A; Dalmau, D; de Mendoza, C; Domingo, P; Estrada, V; Galindo, MJ; Gálvez, J; Martín-Carbonero, L; Ribera, E; Soriano, V | 1 |
Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
Benhamou, Y | 1 |
Ait-Khaled, M; Craig, C; Griffin, P; Stone, C; Tisdale, M | 1 |
Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
Cohen, J | 3 |
Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
Jenny-Avital, ER | 1 |
Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
Farthing, C; Khanlou, H | 1 |
Arnaiz, JA; Blanco, JL; de Lazzari, E; Garrabou, G; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; López, S; Mallolas, J; Martinez, E; Milinkovic, A; Miró, O; Vidal, S | 1 |
Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
Gafni, RI; Hazra, R; Purdy, JB; Reynolds, JC; Zeichner, S | 1 |
Geretti, AM | 1 |
Bischofberger, N; Fridland, A; Kim, C; Robbins, BL; Srinivas, RV | 1 |
Fridland, A; Srinivas, RV | 1 |
Agatep, E; Berardi, CJ; Bischofberger, N; Cundy, KC; Dehqanzada, ZA; Lifson, JD; Marthas, ML; Pedersen, NC; Van Rompay, KK; Vasquez, GM | 1 |
Self, SG; Wick, D | 1 |
Gazzard, BG | 1 |
29 review(s) available for tenofovir and HIV
Article | Year |
---|---|
Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; Polypharmacology | 2018 |
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; History, 20th Century; History, 21st Century; HIV; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2021 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Topics: Anti-HIV Agents; Cerebral Infarction; Drug Combinations; Emtricitabine; Herpesvirus 3, Human; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2023 |
Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review.
Topics: Adenine; Adolescent; Bone Density; Child; HIV; HIV Infections; Humans; Tenofovir | 2023 |
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Drug Prescriptions; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2021 |
The Influence of Cervicovaginal Microbiota on Mucosal Immunity and Prophylaxis in the Battle against HIV.
Topics: Africa South of the Sahara; Anti-HIV Agents; Cervix Uteri; Female; HIV; HIV Infections; Humans; Immunity, Mucosal; Lactobacillus; Microbiota; Pre-Exposure Prophylaxis; Tenofovir; Vagina | 2018 |
Continued Interest and Controversy: Vitamin D in HIV.
Topics: Anti-HIV Agents; Bone Density; Dietary Supplements; Female; HIV; HIV Infections; Humans; Male; Risk; Tenofovir; Vitamin D; Vitamin D Deficiency | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
Topics: Antiretroviral Therapy, Highly Active; Genetic Variation; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Fifty Years in Search of Selective Antiviral Drugs.
Topics: Acyclovir; Antiviral Agents; DNA Virus Infections; DNA Viruses; HIV; HIV Infections; Humans; Molecular Structure; Tenofovir; Valacyclovir | 2019 |
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.
Topics: Anti-Retroviral Agents; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Prevalence; Prognosis; Risk Assessment; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child; Child, Preschool; Deoxyadenine Nucleotides; DNA, Viral; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Liver Diseases; Middle Aged; Molecular Structure; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication; Young Adult | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Diabetic Nephropathies; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Diseases; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Outcome | 2008 |
[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Organophosphonates; Patient Acceptance of Health Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Mutation; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Selection, Genetic; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zalcitabine | 2008 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Risk Assessment; Tenofovir; Viremia | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Occupational Exposure; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Tenofovir | 2010 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Diseases; HIV; HIV Infections; Humans; Hypogonadism; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV; HIV Infections; Humans; Mice; Organophosphonates; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Overview of microbicides for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Resistance testing methodologies and mechanisms of resistance.
Topics: Adenine; Anti-HIV Agents; CCR5 Receptor Antagonists; Drug Resistance, Viral; HIV; Humans; Lopinavir; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Pyrimidinones; Tenofovir | 2007 |
The potential place of tenofovir in antiretroviral treatment regimens.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
21 trial(s) available for tenofovir and HIV
Article | Year |
---|---|
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Topics: Anti-HIV Agents; Diketopiperazines; DNA-Directed RNA Polymerases; Emtricitabine; Female; HIV; HIV Infections; Humans; Nucleosides; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Topics: Adult; Albuminuria; Alpha-Globulins; Anti-HIV Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Pre-Exposure Prophylaxis; Proteinuria; Tenofovir; Transgender Persons; Urine; Young Adult | 2018 |
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Bone and Bones; Bone Density; Cohort Studies; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Tenofovir; Vitamin D; Vitamin D Deficiency; White People; Young Adult | 2018 |
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Topics: Adult; Antiviral Agents; Area Under Curve; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; HIV; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2019 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Parathyroid Hormone; Phosphates; Reverse Transcriptase Inhibitors; Tenofovir; Vitamin D Deficiency; Vitamin D-Binding Protein | 2013 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Family Characteristics; Female; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Male; Mutation, Missense; Placebos; Pre-Exposure Prophylaxis; RNA, Viral; Sequence Analysis, DNA; Tenofovir | 2016 |
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Dried Blood Spot Testing; Drug Administration Schedule; Emtricitabine; Female; Half-Life; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Interactions; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney; Lithium Compounds; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Follow-Up Studies; HIV; HIV Antibodies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Organophosphonates; Patient Compliance; RNA, Viral; Tenofovir; Transsexualism; Young Adult | 2010 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Cholesterol; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lipodystrophy; Male; Middle Aged; Mitochondria; Organophosphonates; Oxygen Consumption; Stavudine; Tenofovir; Treatment Outcome; Triglycerides | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
125 other study(ies) available for tenofovir and HIV
Article | Year |
---|---|
Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
Topics: Adenine; Anti-HIV Agents; Combinatorial Chemistry Techniques; Drug Design; HIV; Molecular Structure; Nucleosides; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tenofovir | 2007 |
PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Molecular Structure; Organophosphonates; Papillomavirus Infections; Prodrugs; Structure-Activity Relationship; Tenofovir; Tumor Cells, Cultured | 2014 |
Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors.
Topics: Alkylation; Amides; Antiviral Agents; Dose-Response Relationship, Drug; Esters; Gallic Acid; Hepacivirus; HIV; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2015 |
Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
Topics: Anti-HIV Agents; Binding Sites; Dendrimers; Dose-Response Relationship, Drug; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; Humans; Microbial Sensitivity Tests; Molecular Structure; Protein Binding; Receptors, HIV; Structure-Activity Relationship; Tryptophan; Tumor Cells, Cultured; Virus Internalization; Virus Replication | 2015 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Evolution of Hepatitis B Virus (HBV) Serologic Markers Among Antiretroviral-Naive Young People Living With Human Immunodeficiency Virus Who Had Undergone Neonatal HBV Vaccination and Initiated Antiretroviral Therapy.
Topics: Adolescent; Adult; Anti-Retroviral Agents; DNA-Directed RNA Polymerases; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Herpesvirus 1, Cercopithecine; HIV; HIV Infections; Humans; Infant, Newborn; Retrospective Studies; Tenofovir; Vaccination; Young Adult | 2022 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Female; HIV; HIV Infections; Humans; Organophosphates; Postpartum Period; Pregnancy; Tenofovir; Viremia | 2022 |
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Tenofovir; United States | 2022 |
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Data Analysis; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Macaca; Necrosis; Simian Immunodeficiency Virus; Tenofovir | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Liquid; Ethanol; Fumarates; HIV; HIV Infections; Humans; Lipids; Organophosphates; Tandem Mass Spectrometry; Tenofovir | 2022 |
Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Namibia; Pre-Exposure Prophylaxis; Public Health; Public Sector; Tenofovir | 2022 |
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection.
Topics: Cohort Studies; Coinfection; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Tenofovir; Viral Load | 2023 |
Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques.
Topics: Animals; HIV; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Sexual and Gender Minorities; Tenofovir | 2022 |
Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir | 2022 |
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
Topics: COVID-19; COVID-19 Vaccines; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
Topics: Bone Density; Bone Diseases, Metabolic; Cohort Studies; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Risk Factors; Switzerland; Tenofovir | 2023 |
Changes in health and sleep quality after anti-retroviral treatment modification in Japanese people living with HIV.
Topics: Anti-Retroviral Agents; Drug Combinations; East Asian People; HIV; HIV Infections; Humans; Male; Quality of Life; Sleep Quality; Tenofovir | 2023 |
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
High rates of tenofovir failure in a CRF01_AE-predominant HIV epidemic in the Philippines.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Epidemics; Female; HIV; HIV Infections; Humans; Male; Philippines; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2020 |
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Kenya; Male; Mass Screening; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Rural Population; Sex Workers; Tenofovir; Uganda; Young Adult | 2020 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Darunavir; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Tenofovir; Viral Load | 2020 |
FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Female; Fibroblast Growth Factors; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Factors; Ritonavir; Tenofovir; Young Adult | 2020 |
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Medication Adherence; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2021 |
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; Gastrointestinal Microbiome; Gene Expression; HIV; HIV Infections; Humans; Interferon Type I; Male; Middle Aged; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transcriptome | 2020 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Immunoassay; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Male; Mutation; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Overcoming the Hydrolytic Lability of a Reaction Intermediate in Production of Protein/Drug Conjugates: Conjugation of an Acyclic Nucleoside Phosphonate to a Model Carrier Protein.
Topics: Adenine; Chromatography, Ion Exchange; Chromatography, Liquid; Cidofovir; Cytosine; HIV; Nucleosides; Organophosphonates; Pharmaceutical Preparations; Protein Binding; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2017 |
The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk.
Topics: Bone Density; Cancellous Bone; Coinfection; Cross-Sectional Studies; Fractures, Bone; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Tenofovir | 2018 |
Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe.
Topics: Adult; Anti-Retroviral Agents; Calcium; Cross-Sectional Studies; Europe; Female; HIV; HIV Infections; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Tenofovir; Vitamin D | 2018 |
Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Epithelium; Estradiol; Female; HIV; HIV Infections; Humans; Menstrual Cycle; Mucous Membrane; Organophosphates; Postmenopause; Premenopause; Tenofovir; Time Factors; Vagina; Vaginal Creams, Foams, and Jellies | 2018 |
Inflammation weakens HIV prevention.
Topics: Acquired Immunodeficiency Syndrome; Female; Genitalia; HIV; HIV Infections; Humans; Inflammation; Tenofovir | 2018 |
Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Ghana; Glomerular Filtration Rate; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Tenofovir; Time Factors | 2018 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Ethics and HIV prevention research: An analysis of the early tenofovir PrEP trial in Nigeria.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biomedical Research; Community Participation; Dissent and Disputes; Ethical Analysis; Ethics, Research; HIV; HIV Infections; Humans; Nigeria; Patient Advocacy; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Research Design; Research Personnel; Tenofovir; Thinking | 2019 |
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Topics: Adult; Anti-HIV Agents; China; Coinfection; DNA-Directed DNA Polymerase; Drug Resistance, Multiple, Viral; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Mutation; Prevalence; Tenofovir; Viral Load | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; China; Communication Barriers; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Perception; Pre-Exposure Prophylaxis; Self Report; Sexual and Gender Minorities; Surveys and Questionnaires; Tenofovir; Young Adult | 2018 |
Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Stavudine; Sustained Virologic Response; Tenofovir; Zidovudine | 2018 |
Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?
Topics: Drug Resistance; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2019 |
Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Predictive Value of Tests; Tenofovir; Viral Load; Viremia | 2019 |
Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Carcinoma, Hepatocellular; Coinfection; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Tenofovir | 2019 |
Prevalence of tubulopathy and association with renal function loss in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Biomarkers; Ethnicity; Female; France; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Tubules; Male; Middle Aged; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Tenofovir | 2020 |
Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Cross-Over Studies; Female; HIV; HIV Infections; Humans; Kenya; Leukocytes, Mononuclear; Male; Organophosphates; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda | 2019 |
Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; Fertilization; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Safe Sex; South Africa; Tenofovir; Young Adult | 2019 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Deoxycytidine; Disease Transmission, Infectious; Drug Resistance, Viral; Emtricitabine; HIV; Macaca; Mutation, Missense; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome | 2013 |
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Health Resources; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Residence Characteristics; RNA, Viral; Stavudine; Tenofovir; Young Adult; Zidovudine | 2013 |
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Primary Health Care; Retrospective Studies; Risk Factors; South Africa; Tenofovir | 2013 |
The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Prognosis; Prospective Studies; Risk Factors; Tenofovir | 2013 |
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Interferons; Limit of Detection; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2013 |
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Topics: Adenine; Administration, Intravaginal; Animals; Delayed-Action Preparations; Drug Delivery Systems; Female; HIV; Lentivirus Infections; Macaca mulatta; Organophosphonates; Simian Immunodeficiency Virus; Tenofovir | 2013 |
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Mothers; Organophosphonates; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Pregnant Women; Prevalence; South Africa; Tenofovir; Viral Load | 2013 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Heterosexuality; HIV; HIV Infections; Humans; Organophosphonates; Plasma; Post-Exposure Prophylaxis; Tenofovir; Viral Load | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV; Humans; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; Young Adult | 2014 |
Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV; Lentivirus Infections; Macaca nemestrina; Organophosphonates; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Vagina | 2014 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antibody Affinity; Cohort Studies; Female; HIV; HIV Antibodies; HIV Infections; Humans; Immunoassay; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Young Adult | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Topics: Administration, Intravaginal; Animals; Disease Models, Animal; Drug Resistance, Viral; Female; Gels; HIV; HIV Infections; Humans; Macaca radiata; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina | 2015 |
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Apolipoproteins E; Bone Density; Bone Diseases, Metabolic; Case-Control Studies; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Osteoporosis; Risk Factors; RNA, Viral; Tenofovir; United States | 2016 |
Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, Liquid; Female; Gels; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Pre-Exposure Prophylaxis; Sex Factors; Tandem Mass Spectrometry; Tenofovir; Time Factors; Vaginal Douching; Young Adult | 2016 |
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Topics: Adult; Coinfection; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Male; Tenofovir; Viral Load | 2016 |
Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genotype; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; South Africa; Tenofovir; Treatment Failure | 2016 |
Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Anti-HIV Agents; Cross-Sectional Studies; Female; Germany; HIV; HIV Infections; Humans; Male; Middle Aged; Prevalence; Proteinuria; Risk Factors; Tenofovir; Young Adult | 2016 |
Is There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar.
Topics: Adolescent; Adult; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Myanmar; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Diphosphates; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Polyphosphates; Prospective Studies; Tenofovir; Young Adult | 2016 |
[Lack of energy in a patient living with HIV].
Topics: Antiviral Agents; Diagnosis, Differential; Fatigue; HIV; HIV Infections; Humans; Kidney; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Renal Dialysis; Tenofovir | 2017 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Kidney Diseases; Liver Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Cell Line; Cellulose; Electric Impedance; Epithelial Cells; HIV; Humans; Inflammation; Naphthalenesulfonates; NF-kappa B; Organophosphonates; Polymers; Tenofovir; Tight Junctions; Virus Replication | 2009 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Trial results finally show potential for microbicidal HIV gel.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; Gels; HIV; HIV Infections; Humans; Organophosphonates; South Africa; Tenofovir; Vagina | 2010 |
Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Child; Child, Preschool; Collagen Type I; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Organophosphonates; Peptides; Tenofovir; Young Adult | 2010 |
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.
Topics: Adenine; Catalytic Domain; Computer Simulation; Drug Resistance, Viral; HIV; HIV Reverse Transcriptase; Humans; Hydrogen Bonding; Kinetics; Mutation, Missense; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Viral; Emtricitabine; HIV; Humans; Macaca; Mutation; Organophosphonates; Recombination, Genetic; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Virus Cultivation | 2011 |
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Deoxycytidine; Drug Combinations; Emtricitabine; HIV; HIV Antibodies; Human Immunodeficiency Virus Proteins; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load | 2011 |
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; United States; White People; Withholding Treatment | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Fetus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Italy; Male; Observation; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Topics: Adenine; Antiviral Agents; Cell Culture Techniques; Chemoprevention; Contraceptive Devices, Female; Female; Herpes Genitalis; HIV; HIV Infections; Humans; Organ Culture Techniques; Organophosphonates; Simplexvirus; Tenofovir | 2012 |
An intravaginal ring for the simultaneous delivery of multiple drugs.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Delivery Systems; Equipment Design; Female; HIV; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Silicon; Tenofovir; Tensile Strength | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Tenofovir helps beat hepatitis B.
Topics: Adenine; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
[Tenofovir (Viread)].
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; HIV; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV; Humans; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Topics: Adenine; Anti-HIV Agents; Cloning, Molecular; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Genotype; HIV; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bupropion; Circumcision, Male; Clinical Trials as Topic; Contraceptive Devices, Female; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV; HIV Infections; Humans; Hygiene; Male; Organophosphonates; Sexual Behavior; Tenofovir; Viral Load | 2005 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Hepacivirus; Hepatitis B virus; HIV; Humans; Organophosphonates; Papillomaviridae; Poxviridae; Tenofovir; Virus Diseases; Viruses | 2007 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2008 |
Test of new vaginal microbicide gel show promise for women.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Anti-Infective Agents, Local; Anti-Retroviral Agents; Female; HIV; HIV Seronegativity; Humans; India; Organophosphonates; Safety; Tenofovir; Treatment Outcome; United States; Vaginal Creams, Foams, and Jellies | 2008 |
AIDS research. New drug shows promise in monkeys.
Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 1995 |
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.
Topics: Adenine; Anti-HIV Agents; Blood Platelets; HIV; Humans; Leukocytes, Mononuclear; Organophosphonates; Organophosphorus Compounds; Prodrugs; T-Lymphocytes; Tenofovir | 1998 |
Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.
Topics: Adenine; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; HIV; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virion | 1998 |
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Pregnancy; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome | 1998 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Humans; Macaca; Macrophages; Models, Immunological; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Soman; Stochastic Processes; Tenofovir; Time Factors; Viral Load | 2000 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personnel; HIV; HIV Infections; Humans; Macaca; Nevirapine; Occupational Diseases; Organophosphonates; Organophosphorus Compounds; Pan troglodytes; Pyridines; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Tenofovir; United States; Zidovudine | 1997 |
Vaccines. Monkey puzzles.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS Vaccines; Animals; Anti-HIV Agents; Clinical Trials as Topic; Haplorhini; HIV; Humans; Killer Cells, Natural; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; SAIDS Vaccines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viremia | 2002 |